In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. The topics covered include:When to use cytoreduction therapies and which therapies to use in low-risk patientsType 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reportsExperts’ thoughts on therapy options in higher-risk patientsPresenters:Prithviraj Bose, MDAssociate ProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of TexasMD Anderson Cancer CenterHouston, TexasAndrew Kuykendall, MDAssistant Professor Department of Oncologic SciencesUniversity of South FloridaAssistant MemberMalignant HematologyH. Lee Moffitt Cancer CenterTampa, Florida Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.Link to the full program, including downloadable slides and an on-demand webcast from the live event:bit.ly/3XF3cSF

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related